FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to psychiatry, and can be used to assess the effectiveness of using N-acetylcysteine (NAC) in patients with schizophrenia aged 18 to 45 years old, living with this disease for up to 3 years and in remission, receiving antipsychotics. Patient’s blood is sampled, and the level of non-enzymatic antioxidant reduced glutathione (GSH) in blood serum is measured. Standard values for GSH are set at the level higher than 950 mcmol/l. If the GSH level is below the standard values, N-acetylcysteine (NAC) is used in addition to the antipsychotics in dose of 2000 mg day for 8 weeks. After 8 weeks, the blood GSH level is reassessed. If the GSH level is more than 950 mcmol/l, the effectiveness of using NAC in patients with schizophrenia is determined.
EFFECT: method enables stratification of schizophrenic patients who are most likely to respond to antioxidant therapy; improved understanding of the effect of NAC on various aspects of schizophrenia, including cognitive functions and psychopathological symptoms; assessing the safety of using NAC as an augmentation to the main pharmacotherapy, taking into account the observed minimum risk of developing side effects; by measuring the level of GSH in the blood of the patients receiving antipsychotics, in addition to the antipsychotics of using NAC for 8 weeks with the level of GSH below the standard values, re-assessing the level of GSH in the blood of patients after 8 weeks.
1 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTING THE EFFECTIVENESS OF TREATMENT OF PATIENTS WITH SCHIZOPHRENIA | 2021 |
|
RU2775440C1 |
| COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF, AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF AND AT LEAST ONE NICOTINAMIDE RIBOSIDE OR NAD+ PRECURSOR | 2019 |
|
RU2820163C2 |
| METHOD FOR PREDICTING THE EFFICIENCY OF TREATING PATIENTS WITH SCHIZOPHRENIA WITH ATYPICAL NEUROLEPTIC QUETIAPIN (SEROQUEL) | 2005 |
|
RU2289137C1 |
| METHOD FOR PREDICTING EFFECTIVENESS OF OLANZAPINE ATYPICAL ANTIPSYCHOTIC DRUG THERAPY IN SCHIZOPHRENIA PATIENTS | 2017 |
|
RU2680529C1 |
| METHOD OF DETERMINING THE NECESSITY OF USING PSYCHO PHARMACOTHERAPY AMONG THE PATIENTS WITH DISORDERS OF AUTIST SPECTRUM AT THE MOMENT OF THEIR EXAMINATION | 2017 |
|
RU2643760C1 |
| METHOD FOR PREDICTION OF THE PROBABILITY OF AN UNFAVORABLE OUTCOME IN RELATION TO THE SOCIAL POSTPSYCHOTIC FUNCTIONING OF THE PATIENTS WITH ENDOGENOUS PSYCHIC DISEASES | 2018 |
|
RU2706216C1 |
| METHOD FOR PREDICTION OF RISK OF DELAYED DYSKINESIA ACCOMPANYING NEUROLEPTIC THERAPY IN SCHIZOPHRENICS | 2010 |
|
RU2447832C1 |
| POWDER CONTAINING BUFFER SALT AND AMINO ACID, DISSOLUTION OF SUCH POWDER TO NUTRIENT PRODUCT AND METHODS OF USE OF SUCH NUTRIENT PRODUCT | 2019 |
|
RU2810755C2 |
| DIAGNOSTIC TECHNIQUE FOR ASTHENIC SYNDROME IN SCHIZOPHRENIC PATIENTS | 2019 |
|
RU2709105C1 |
| METHOD FOR PREDICTION OF CLINICAL EFFECTIVENESS IN SCHIZOPHRENIC PATIENTS | 2014 |
|
RU2546021C1 |
